	INTRODUCED BY T. MCGILLVRAY	
	BY REQUEST OF THE DEPARTMENT OF JUSTICE	
A BILL FOR A	N ACT ENTITLED: "AN ACT GENERALLY REVISING DRUG SCHEDULES FOR SCHEDULE I,	
SCHEDULE II,	SCHEDULE III, SCHEDULE IV, AND SCHEDULE V CONTROLLED SUBSTANCES;	
PROVIDING UPDATES TO EACH LISTED SCHEDULE; AND AMENDING SECTIONS 50-32-222, 50-32-224		
50-32-226, 50-	32-229, AND 50-32-232, MCA."	
BE IT ENACTE	D BY THE LEGISLATURE OF THE STATE OF MONTANA:	
Sectio	n 1. Section 50-32-222, MCA, is amended to read:	
"50-32	-222. Specific dangerous drugs included in Schedule I. Schedule I consists of the drugs	
and other subs	tances, by whatever official, common, usual, chemical, or brand name designated, listed in this	
section.		
(1)	Opiates. Unless specifically excepted or listed in another schedule, any of the following are	
opiates, includi	ng isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the	
existence of the	ose isomers, esters, ethers, and salts is possible within the specific chemical designation:	
(a)	acetyl-alpha-methylfentanyl, also known as N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-	
phenylacetami	de;	
(b)	acetylmethadol, also known as 4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate or	
methadyl acetate;		
(c)	allylprodine, also known as 1-methyl-4-phenyl-3-(prop-2-en-1-yl)piperidin-4-yl propanoate;	
(d)	alphacetylmethadol, except levo-alphacetylmethadol, also known as levo-alpha-	
acetylmethadol, levomethadyl acetate, or LAAM;		
(e)	alphameprodine;	
(f)	alphamethadol;	
(g)	alpha-methylfentanyl, also known as (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]	
	SCHEDULE II, PROVIDING U 50-32-226, 50-3 BE IT ENACTE Section "50-32- and other substance of the (a) phenylacetamic (b) methadyl aceta (c) (d) acetylmethadol (e) (f)	



```
1
       propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
 2
               (h)
                        alpha-methylthiofentanyl, also known as N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-
 3
       phenylpropanamide;
 4
               (i)
                        benzethidine;
 5
               (j)
                        betacetylmethadol;
 6
               (k)
                        beta-hydroxyfentanyl, also known as N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-
 7
       phenylpropanamide;
 8
                        beta-hydroxy-3-methylfentanyl, also known as N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
               (I)
 9
       piperidinyl]-N-phenylpropanamide;
10
               (m)
                        betameprodine;
11
               (n)
                        betamethadol;
12
                        betaprodine;
               (o)
13
               (p)
                        brorphine
14
               (p)(q)
                        clonitazene;
15
               <del>(q)</del>(r)
                        dextromoramide;
16
               <del>(r)</del>(s)
                        diampromide;
17
               (s)(t)
                        diethylthiambutene;
18
                        difenoxin;
               <del>(t)</del>(u)
19
               <del>(u)</del>(v)
                        dimenoxadol;
20
               (v)(w)
                        dimepheptanol;
21
               <del>(w)(x)</del>
                        dimethylthiambutene;
22
               (x)(y)
                        dioxaphetyl butyrate;
23
               (<u>y)(z)</u>
                        dipipanone;
24
               (z)(aa) ethylmethylthiambutene;
25
               (aa)(bb) etonitazene;
               (bb)(cc) etoxeridine;
26
27
                       fluorofentanyl
               (dd)
28
               (cc)(ee) furethidine;
```



```
1
              (dd)(ff) hydroxypethidine;
 2
                      isotonitazene
              (gg)
 3
              (ee)(hh) ketobemidone;
 4
              (ff)(ii) levomoramide;
 5
              (gg)(jj) levophenacylmorphan;
 6
              (hh)(kk) 3-methylfentanyl, also known as N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-
7
      phenylpropanamide;
8
              (ii)(II) 3-methylthiofentanyl, also known as N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-
9
      phenylpropanamide (optical and geometric isomers only);
10
              (ii)(mm) morpheridine;
11
              (kk)(nn) MPPP, also known as desmethylprodine and (1-methyl-4-phenyl-4-propionoxypiperidine);
12
              (II)(oo) noracymethadol;
13
              (mm)(pp) norlevorphanol;
14
              (nn)(qq) normethadone;
15
              (oo)(rr) norpipanone;
16
              (pp) para-fluorofentanyl, also known as N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
17
      piperidinyl]propanamide;
18
              (qq)(ss) PEPAP, also known as (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
19
              (rr)(tt) phenadoxone;
20
              (ss)(uu) phenampromide;
21
              (tt)(vv) phenomorphan;
22
              (uu)(ww) phenoperidine;
23
              (vv)(xx) piritramide;
24
              (ww)(yy) proheptazine;
25
              (xx)(zz) properidine;
26
              (yy)(aaa) propiram;
27
              (zz)(bbb) racemoramide;
28
              (aaa)(ccc) thiofentanyl, also known as N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide;
```



68th Legislature 2023 SB 67.1

1 (bbb)(ddd) tilidine; and 2 (ccc)(eee) trimeperidine. 3 For the purposes of subsection (1)(hh), the term "isomer" includes the optical, positional, and (2) 4 geometric isomers. Substituted fentanyls (1-phenethyl-4-N-propionylanilinopiperidine) are, unless specifically 5 excepted, listed in another schedule, approved by the United States food and drug administration, or not used 6 within legitimate and approved medical research, any material, compound, mixture, or preparation, including its 7 salts, isomers, esters, ethers, and salts of isomers, esters, or ethers whenever the existence of those salts is 8 possible, within any of the following chemical designations that are structurally related to fentanyl by one or 9 more of the following modifications: 10 replacement of the phenyl portion of the phenethyl group by any monocyclic ring, whether or 11 not further substituted in or on the monocyclic ring; 12 substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, 13 amino, or nitro groups; 14 substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, (c) 15 haloalkyl, amino, or nitro groups; 16 replacement of the aniline ring with any aromatic monocyclic ring, whether or not further 17 substituted in or on the aromatic monocyclic ring; or 18 replacement of the N-propionyl group by another acyl group. <u>(e)</u> 19 (3)Opium derivatives. Unless specifically excepted or listed in another schedule, any of the 20 following are opium derivatives, including salts, isomers, and salts of isomers whenever the existence of those 21 salts, isomers, and salts of isomers is possible within the specific chemical designation: 22 (a) acetorphine; 23 (b) acetyldihydrocodeine; benzylmorphine; 24 (c) 25 (d) codeine methylbromide; 26 (e) codeine-N-oxide; cyprenorphine; 27 (f) 28 (g) desomorphine;



68th Legislature 2023 SB 67.1

1 (h) dihydromorphine; 2 (i) drotebanol; 3 (j) etorphine, except hydrochloride salt; 4 (k) heroin; 5 (I) hydromorphinol; 6 (m) methyldesorphine; 7 methyldihydromorphine; (n) 8 (o) morphine methylbromide; 9 morphine methylsulfonate; (p) 10 morphine-N-oxide; (q) 11 (r) myrophine; 12 (s) nicocodeine; 13 (t) nicomorphine; 14 normorphine; (u) 15 (v) pholcodine; and 16 (w) thebacon. 17 (4) Hallucinogenic substances. Unless specifically excepted or listed in another schedule, any 18 material, compound, mixture, or preparation that contains any quantity of the following is a hallucinogenic 19 substance, including salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and 20 salts of isomers is possible within the specific chemical designation: 21 alpha-ethyltryptamine, also known as etryptamine, monase, alpha-ethyl-1H-indole-3-(a) 22 ethanamine, 3-(2-aminobutyl) indole, alpha-ET, and AET; 23 (b) alpha-methyltryptamine, also known as AMT; 24 4-bromo-2,5-dimethoxyamphetamine, also known as 4-bromo-2, 5-dimethoxy-alpha-(c) 25 methylphenethylamine, and 4-bromo-2,5-DMA; 26 (d) 4-bromo-2,5-dimethoxyphenethylamine, also known as 2-(4-bromo-2,5-dimethoxyphenyl)-1-27 aminoethane, alpha-desmethyl DOB, and 2C-B, Nexus;



(e)

28

2,5-dimethoxyamphetamine, also known as 2,5-dimethoxy-alpha-methylphenethylamine and

1	2,5-DMA;	
2	(f)	2,5-dimethoxy-4-(N)-propylthiophenethylamine, also known as 2C-T-7;
3	(g)	3,4-methylenedioxyamphetamine;
4	(h)	2,5-dimethoxy-4-ethylamphetamine, also known as DOET;
5	(i)	5-methoxy-N,N-diisopropyltryptamine, also known as 5-MeO-DIPT;
6	(j)	5-methoxy-N,N-dimethyltryptamine, also known as 5-MeO-DMT;
7	(k)	4-methoxyamphetamine, also known as 4-methoxy-alpha-methylphenethylamine;
8	(I)	5-methoxy-3,4-methylenedioxyamphetamine;
9	(m)	4-methyl-2,5-dimethoxyamphetamine, also known as 4-methyl-2, 5-dimethoxy-alpha-
10	methylpheneth	ylamine, DOM, and STP;
11	(n)	3,4-methylenedioxymethamphetamine, also known as MDMA;
12	(o)	3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-alpha-methyl-
13	3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, and MDEA;	
14	(p)	N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-methyl-3,4
15	(methylenediox	y)phenethylamine and N-hydroxy MDA;
16	(q)	3,4,5-trimethoxyamphetamine;
17	(r)	bufotenine, also known as 3-(beta-dimethylaminoethyl)-5-hydroxyindole, 3-(2-
18	dimethylaminoethyl)-5-indolol, N,N-dimethylserotonin, 5-hydroxy-N,N-dimethyltryptamine, and mappine;	
19	(s)	diethyltryptamine, also known as N,N-diethyltryptamine and DET;
20	(t)	dimethyltryptamine, also known as DMT;
21	(u)	hashish;
22	(v)	ibogaine, also known as 7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-
23	pyrido [1', 2':1,2	2] azepine [5,4-b] indole and tabernanthe iboga;
24	(w)	lysergic acid diethylamide, also known as LSD;
25	(x)	marijuana;
26	(y)	mescaline;
27	(z)	parahexyl, also known as 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,8 6,9-trimethyl-6H-
28	dibenzo[b,d]py	ran and synhexyl;



11

12

13

14

15

21

22

23

25

26

27

28

68th Legislature 2023 SB 67.1

1 (aa) peyote, meaning all parts of the plant presently classified botanically as lophophora williamsii 2 lemaire, whether growing or not; the seed of the plant; any extract from any part of the plant; and every 3 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed, or extracts: 4 (bb) N-ethyl-3-piperidyl benzilate; 5 (cc) N-methyl-3-piperidyl benzilate; 6 (dd) psilocybin; 7 (ee) psilocyn, also known as psilocin; 8 (ff) tetrahydrocannabinols, neutral compounds, and their corresponding acids, including synthetic 9 equivalents of the substances contained in the plant or in the resinous extractives of cannabis, or synthetic 10 substances, derivatives, and their isomers with similar chemical structure and pharmacological activity, such as

those listed in subsections (4)(ff)(i) through (4)(ff)(iii). Because nomenclature of these substances is not

internationally standardized, compounds of these structures, regardless of numerical designation of atomic

(i) delta 4 9 (delta 9 1) cis or trans tetrahydrocannabinol and its optical isomers;

positions covered, are included in the category as follows:

- (ii) delta 6 8 (delta 6) cis or trans tetrahydrocannabinol and its optical isomers; and
- 16 (iii) delta 6a, 10a, (delta 3,4) cis or trans tetrahydrocannabinol and its optical isomers;
- 17 (gg) ethylamine analog of phencyclidine, also known as N-ethyl-1-phenylcyclohexylamine, (1-18 phenylcyclohexyl)ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, and PCE;
- 19 (hh) pyrrolidine analog of phencyclidine, also known as 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, 20 and PHP;
 - (ii) thiophene analog of phencyclidine, also known as 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienyl analog of phencyclidine, TPCP, and TCP;
 - (jj) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, also known as TCPy;
- 24 (kk) synthetic cannabinoids, including:
 - (i) unless specifically excepted or listed in another schedule, any chemical compound chemically synthesized from or structurally similar to any material, compound, mixture, or preparation that contains any quantity of a synthetic cannabinoid found in any of the following chemical groups, or any of those groups that contain synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of those salts,



5

6

15

16

19

20

21

22

68th Legislature 2023 SB 67.1

isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic
 cannabinoid chemical analogs in the following groups:

- 3 (A) naphthoylindoles, whether or not substituted in the indole ring to any extent or the naphthyl ring 4 to any extent;
 - (B) naphthylmethylindoles, whether or not substituted in the indole ring to any extent or the naphthyl ring to any extent;
- 7 (C) naphthoylpyrroles, whether or not substituted in the pyrrole ring to any extent or the naphthyl 8 ring to any extent;
- 9 (D) naphthylmethylindenes, whether or not substituted in the indene ring to any extent or the naphthyl ring to any extent;
- 11 (E) acetylindoles, whether or not substituted in the indole ring to any extent or the acetyl group to 12 any extent;
- 13 (F) cyclohexylphenols, whether or not substituted in the cyclohexyl ring to any extent or the phenyl 14 ring to any extent;
 - (G) dibenzopyrans, whether or not substituted in the cyclohexyl ring to any extent or the phenyl ring to any extent; and
- 17 (H) benzoylindoles, whether or not substituted in the indole ring to any extent or the phenyl ring to 18 any extent;
 - (ii) any compound that has been demonstrated to have agonist binding activity at one or more cannabinoid receptors or is a chemical analog or isomer of a compound that has been demonstrated to have agonist binding activity at one or more cannabinoid receptors;
 - (iii) 1-pentyl-3-(1-naphthoyl)indole (also known as JWH-018);
- 23 (iv) (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-24 tetrahydrobenzo[c]chromen-1-ol (also known as HU-210 or 1,1-dimethylheptyl-11-hydroxy-delta8-25 tetrahydrocannabinol):
- 26 (v) 2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (also known as CP-47,497), and the dimethylhexyl, dimethyloctyl, and dimethylnonyl homologues of CP-47,497;
- 28 (vi) 1-butyl-3-(1-naphthoyl)indole (also known as JWH-073);



7

8

11

14

15

16

17

18

19

20

21

22

23

24

25

1 (vii) 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl) indole (also known as	JWH-200);
--	-----------

- 2 (viii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (also known as JWH-250);
- 3 (ix) 1-hexyl-3-(1-naphthoyl)indole (also known as JWH-019);
- 4 (x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (also known as JWH-398);
- 5 (xi) JWH-081: 1-pentyl-3-(4-methoxy-1-naphthoyl)indole, also known as 4-methoxynaphthalen-1-yl-6 (1-pentylindol-3-yl)methanone;
 - (xii) the following substances, except where contained in cannabis or cannabis resin, namely tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives:
- 9 (A) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-10 napthalenylmethanone (also known as WIN-55,212-2);
 - (B) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (also known as HU-243); or
- 12 (C) [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-13 1-yl]acetate;
 - (II) Salvia divinorum, also known as salvinorin A (2S,4aR,6aR,7R,9S,10aS,10bR)-9- (acetyloxy)-2- (3-furanyl)dodecahydro-6a,10b-dimethyl-4, 10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic acid methyl ester;
 - (mm) substituted cathinones, including any compound, except bupropion or compounds listed in another schedule, in an administrative rule regulating controlled substances, or approved for use by the United States food and drug administration, that is structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:
 - (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
 - (ii) by substitution at the 3-position with an alkyl substituent;
 - (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure; and
- 26 (iv) any lengthening of the propanone chain between carbons 1 and 2 to any extent with alkyl groups, whether further substituted or not;
- 28 (nn) <u>substituted amphetamines, including</u> any compound not listed in this code, except compounds



10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

68th Legislature 2023 SB 67.1

1 <u>listed in another schedule,</u> in an administrative rule regulating controlled substances, or approved for use by the

- 2 United States food and drug administration, that is structurally derived from 2-amino-1-phenyl-1-propane 2
- 3 <u>aminopropane</u> by modification in any of the following ways:
- by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
- 7 (ii) by substitution at the 3-position with an alkyl substituent;
- 8 (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen 9 atom in a cyclic structure; and
 - (iv) any lengthening of the propane chain between carbons 1 and 2 to any extent with alkyl groups, whether further substituted or not.
 - (5) (a) For the purposes of subsection (4), the term "isomer" includes the optical, positional, and geometric isomers.
 - (b) Subsection (4)(kk) does not apply to synthetic cannabinoids approved by the United States food and drug administration and obtained by a lawful prescription through a licensed pharmacy. The department of public health and human services shall adopt a rule listing the approved cannabinoids and shall update the rule as necessary to keep the list current.
 - (6) Depressants. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is a depressant having a depressant effect on the central nervous system, including salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
 - (a) gamma-hydroxybutyric acid, also known as gamma-hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium oxybate, sodium oxybutyrate, and GHB;
 - (b) mecloqualone; and
- 26 (c) methagualone;
- 27 (d) substituted benzodiazepines, unless specifically excepted, listed in another schedule, in an
 28 administrative rule regulating controlled substances, approved for use by the United States food and drug



68th Legislature 2023 SB 67.1

1 administration, or not used within legitimate and approved medical research, any material, compound, mixture, 2 or preparation, including its salts, isomers, and salts of isomers whenever the existence of such salts is 3 possible, within any of the following chemical designations that are structurally related to: 4 (A) a 1,4-benzodiazepine structure with any substitution at the 5-position, whether or not the 1,4-5 benzodiazepine is further substituted; 6 a 1,4-benzodiazepine structure fused with a triazole ring to form a triazolobenzodiazepine (B) 7 structure with any substitution at the 6-position, whether or not the triazolobenzodiazepine is further substituted; 8 a 1.4-diazepine ring fused with a thiophene ring and triazole ring to form a 9 thienotriazolodiazepine structure with any substitution at the 4-position, whether or not the 10 thienotriazolodiazepine is further substituted; 11 a 1,4-diazepin-one ring fused with a thiophene ring to form a thienodiazepine structure with any 12 substitution at the 5-position, whether or not the thienodiazepine is further substituted; 13 a 1,5-benzodiazepine structure with any substitutions at the 4-position, whether or not the 1,5-14 benzodiazepine is further substituted; or 15 (F) a 1,5-benzodiazepine structure with any substitutions at the 5- nitrogen position, whether or not 16 the 1,5-benzodiazpine is further substituted. 17 Any compound that meets the criteria in subsection (6)(d) but is designated as a Schedule II, (7) Schedule III, Schedule IV, or Schedule V controlled substance under federal law, will be placed in the same 18 19 Schedule as under federal law. 20 Stimulants. Unless specifically excepted or listed in another schedule, any material, compound, 21 mixture, or preparation that contains any quantity of the following substances is a stimulant having a stimulant 22 effect on the central nervous system, including its salts, isomers, and salts of isomers: 23 (a) aminorex, also known as aminoxaphen, 2-amino-5-phenyl-2-oxazoline, and 4,5-dihydro-5-24 phenyl-2-oxazolamine; 25 (b) cathinone, also known as 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-26 aminopropiophenone, and norephedrone; 27 (c) fenethylline;



(d)

28

methcathinone, also known as 2-(methylamino)-propiophenone, alpha-

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

68th Legislature 2023 SB 67.1

1 (methylamino)propiophenone, 2-(methylamino)-1-phenylpropan-1-one, alpha-N-methylaminopropiophenone,

- 2 monomethylpropion, ephedrone, N-methylcathinone, methylcathinone, AL-464, AL-422, AL-463, and UR1432,
- 3 including its salts, optical isomers, and salts of optical isomers;
- 4 (e) 4-Methylaminorex (cis isomer), also known as U4Euh, McN-422;
- 5 (f) (levo-dextro) cis-4-methylaminorex, also known as (levo-dextro) cis-4, 5-dihydro-4-methyl-5-6 phenyl-2-oxazolamine;
- 7 (g) N-benzylpiperazine, also known as 1-benzylpiperazine or BZP;
- 8 (h) N-ethylamphetamine; and
- 9 (i) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine and N,N-10 alpha-trimethylphenethylamine.
- 11 (8)(9) Substances subject to emergency scheduling. Any material, compound, mixture, or preparation 12 that contains any quantity of the following substances is included in this category:
 - (a) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts, and salts of isomers); and
 - (b) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts, and salts of isomers).
 - (9)(10) If prescription or administration is authorized by the Federal Food, Drug and Cosmetic Act, then any material, compound, mixture, or preparation containing tetrahydrocannabinols listed in subsection (4) must automatically be rescheduled from Schedule I to the same schedule it is placed in by the United States drug enforcement administration.
 - (10)(11) Dangerous drug analogues. Unless specifically excepted or listed in another schedule, this designation includes any material, compound, mixture, or preparation defined in 50-32-101 as a dangerous drug analogue."

Section 2. Section 50-32-224, MCA, is amended to read:

"50-32-224. Specific dangerous drugs included in Schedule II. Schedule II consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this section.



68th Legislature 2023 SB 67.1

1 (1) Substances, vegetable origin or chemical synthesis. Unless specifically excepted or listed in 2 another schedule, any of the following substances, whether produced directly or indirectly by extraction from 3 substances of vegetable origin, independently by means of chemical synthesis, or by a combination of 4 extraction and chemical synthesis, are included in this category: 5 (a) opium and opiate and any salt, compound, derivative, or preparation of opium or opiate, 6 excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, 7 naloxone, 6β-naltrexol, naltrexone, and naloxegol, and samidorphan and their respective salts, but including the 8 following: 9 (i) raw opium; 10 (ii) opium extracts; 11 (iii) opium fluid; 12 (iv) powdered opium; 13 (v) granulated opium; 14 (vi) tincture of opium; 15 (vii) codeine; 16 (viii) dihydroetorphine; 17 (ix) ethylmorphine; etorphine hydrochloride; 18 (x) 19 (xi) hydrocodone: 20 hydromorphone; (xii) 21 (xiii) metopon; 22 (xiv) morphine; 23 (xv)noroxymorphone; 24 (xv)(xvi) oripavine; 25 (xvi)(xvii) oxycodone; 26 (xvii)(xviii) oxymorphone; and 27 (xviii)(xix) thebaine; 28 (b) any salt, compound, derivative, or preparation of them that is chemically equivalent or identical



68th Legislature 2023 SB 67.1

1 with any of the substances referred to in subsection (1)(a), except that these substances do not include the 2 isoquinoline alkaloids of opium; 3 (c) opium poppy and poppy straw; 4 (d) coca leaves and any salt, compound, derivative, or preparation of coca leaves, including 5 cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers, and derivatives, and any salt, 6 compound, derivative, or preparation of them that is chemically equivalent or identical with any of these 7 substances, except that these substances do not include: 8 (i) decocainized coca leaves or extraction of coca leaves, which extractions do not contain 9 cocaine or ecgonine; and or; 10 (ii) [123] lioflupane. 11 (e) concentrate of poppy straw, the crude extract of poppy straw in either liquid, solid, or powder 12 form that contains the phenanthrene alkaloids of the opium poppy. 13 (2) Opiates. Unless specifically excepted or listed in another schedule, any of the following are 14 opiates, including isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the 15 existence of those isomers, esters, ethers, and salts is possible within the specific chemical designation, 16 dextrorphan and levopropoxyphene excepted: 17 alfentanil; (a) 18 (b) alphaprodine; 19 (c) anileridine; 20 (d) bezitramide; 21 bulk dextropropoxyphene (nondosage forms); (e) 22 (f) carfentanil; 23 (g) dihydrocodeine; 24 diphenoxylate; (h) 25 (i) fentanyl; 26 (j) isomethadone; 27 (k) levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, and 28 LAAM;



1		(I)	levomethorphan;
2		(m)	levorphanol;
3		(n)	metazocine;
4		(o)	methadone;
5		(p)	methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
6		(q)	moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
7		<u>(r)</u>	oliceridine N-[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-
8	yl]ethyl))amine)	
9		(r) (s)	pethidine, also known as meperidine;
10		(s) (t)	pethidine-intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
11		(t) (u)	pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
12		(u) (v)	pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
13		(v) (w)	phenazocine;
14		(w) (x)	piminodine;
15		(x) (y)	racemethorphan;
16		(y) (z)	racemorphan;
17		(z) (aa)	remifentanil;
18		(aa) (bb	<u>)</u> sufentanil;
19		(bb) (cc) tapentadol; and
20		(cc) (dd	<u>)</u> thiafentanil.
21		(3)	Stimulants. Unless specifically excepted or listed in another schedule, any material, compound,
22	mixture	, or prep	paration that contains any quantity of the following substances is a stimulant having a stimulant
23	effect on the central nervous system:		
24		(a)	amphetamine, its salts, optical isomers, and salts of its optical isomers;
25		(b)	phenmetrazine and its salts;
26		(c)	lisdexamfetamine, its salts, isomers, and salts of its isomers;
27		(d)	methamphetamine, its salts, isomers, and salts of its isomers; and
28		(e)	methylphenidate.



68th Legislature 2023 SB 67.1

1 (4) Depressants. Unless specifically excepted or listed in another schedule, any material, 2 compound, mixture, or preparation that contains any quantity of the following substances is a depressant 3 having a depressant effect on the central nervous system, including salts, isomers, and salts of isomers 4 whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical 5 designation: 6 (a) amobarbital; 7 (b) glutethimide; 8 (c) pentobarbital; 9 (d) phencyclidine; and 10 secobarbital. (e) 11 (5) Hallucinogenic substances include the following: 12 (a) dronabinol in oral solution in a drug product approved for marketing by the United States food 13 and drug administration; 14 (b) nabilone, also known as (levo-dextro)-trans-3-(1, 1-dimethylheptyl)-6,6-alpha,7,8,10,10-alpha-15 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b, d] pyran-9-one. 16 (6)Immediate precursors. Unless specifically excepted or listed in another schedule, any material, 17 compound, mixture, or preparation that contains any quantity of the following substances is an immediate 18 precursor: 19 (a) 4-Anilino-N-phenethyl-4-piperidine (ANPP); 20 (b) phenylacetone, an immediate precursor to amphetamine and methamphetamine, also known 21 as phenyl-2-propanone, P2P, benzyl methyl ketone, and methyl benzyl ketone; and 22 (c) 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile (PCC), immediate 23 precursors to phencyclidine (PCP); and 24 N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)." (d) 25 26 **Section 3.** Section 50-32-226, MCA, is amended to read: 27 "50-32-226. Specific dangerous drugs included in Schedule III. Schedule III consists of the drugs



28

and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this

2

3

4

5

6

14

15

16

17

18

19

20

21

68th Legislature 2023 SB 67.1

1 section.

(1) Stimulants. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is a stimulant having a stimulant effect on the central nervous system, including salts, isomers (whether optical, position, or geometric), and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 7 (a) benzphetamine;
- 8 (b) chlorphentermine;
- 9 (c) clortermine; and
- 10 (d) phendimetrazine.
- 12 (2) Depressants. Unless specifically excepted or listed in another schedule, any material,
 12 compound, mixture, or preparation that contains any quantity of the following substances is a depressant
 13 having a depressant effect on the central nervous system:
 - (a) any compound, mixture, or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of any of these drugs and one or more other active medicinal ingredients that are not listed in any schedule;
 - (b) any suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of any of these drugs approved by the United States food and drug administration for marketing only as a suppository;
 - (c) any substance that contains any quantity of a derivative of barbituric acid or any salt of barbituric acid;
- 22 (d) aprobarbital;
- (e) butabarbital, also known as secbutabarbital;
- 24 (f) butalbital;
- 25 (g) butobarbital, also known as butethal;
- 26 (h) chlorhexadol;
- 27 (i) embutramide;
- 28 (j) gamma hydroxybutyric acid preparations;



68th Legislature 2023 SB 67.1

1 (k) ketamine, its salts, isomers, and salts of its isomers, also known as (±)-2-(2-chlorophenyl)-2-2 (methylamino)cyclohexanone; 3 (l) lysergic acid; 4 (m) lysergic acid amide; 5 (n) methyprylon; 6 (o) sulfondiethylmethane; 7 sulfonethylmethane; (p) 8 (q) sulfonmethane; 9 (r) talbutal; 10 (s) tiletamine and zolazepam or any of their salts. A trade or other name for a tiletamine-11 zolazepam combination product is telazol. A trade or other name for tiletamine is 2-(ethylamino)-2-(2-thienyl)-12 cyclohexanone. A trade or other name for zolazepam is 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-13 [3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon. 14 (t) thiamylal; 15 (u) thiopental; and 16 (v) vinbarbital. 17 (3) Nalorphine. 18 (4) Narcotic drugs. Unless specifically excepted or listed in another schedule, any material, 19 compound, mixture, or preparation containing any of the following is a narcotic drug, including its salts 20 calculated as the free anhydrous base or alkaloid in the following limited quantities: 21 not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per (a) 22 dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; 23 (b) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per 24 dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; 25 not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams (c)



(d)

26

27

28

not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams

per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

68th Legislature 2023 SB 67.1

1 (e) not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 2 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; 3 (f) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more 4 active, nonnarcotic ingredients in recognized therapeutic amounts; or 5 (g) any material, compound, mixture, or preparation containing buprenorphine. 6 (5) Anabolic steroids. The term "anabolic steroid" means any drug or hormonal substance, 7 chemically and pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids, 8 that promotes muscle growth. Unless specifically excepted or listed in another schedule, any material, 9 compound, mixture, or preparation containing any quantity of the following substances is an anabolic steroid. 10 including its salts, isomers, esters, or ethers and salts of isomers, esters, and ethers whenever the existence of 11 those salts of isomers is possible within the specific chemical designation: 12 (a) androstanedione, also known as 5-alpha-androstan-3,17-dione; 13 (b) 1-androstenediol, also known as 3-beta,17-beta-dihydroxy-5-alpha-androst-1-ene; or 3-alpha, 14 17-beta-dihydroxy-5-alpha-androst-1-ene; 15 (c) 1-androstenedione, also known as 5-alpha-androst-1-en-3,17-dione; 16 (d) 3-alpha,17-beta-dihydroxy-5-alpha-androstane; 17 3-beta, 17-beta-dihydroxy-5-alpha-androstane; (e) 18 (f) 4-androstenediol, also known as 3-beta,17-beta-dihydroxy-androst-4-ene; 19 4-androstenedione, also known as androst-4-en-3,17-dione; (g) 20 (h) 4-dihydrotestosterone, also known as 17-beta-hydroxyandrostan-3-one; 21 (i) 4-hydroxy-19-nortestosterone, also known as 4,17-beta-dihydroxy-estr-4-en-3-one; 22 (j) 4-hydroxytestosterone, 4,17-beta-dihydroxy-androst-4-en-3-one; 23 (k) 5-androstenediol, also known as 3-beta,17-beta-dihydroxy-androst-5-ene; 24 (I) 5-androstenedione, also known as androst-5-en-3,17-dione; 25 (m) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one; 26 (n) 17-alpha-methyl-3-alpha, 17-beta-dihydroxy-5-alpha-androstane; 27 (o) 17-alpha-methyl-3-beta, 17-beta-dihydroxy-5-alpha-androstane; 28 17-alpha-methyl-3-beta, 17-beta-dihydroxyandrost-4-ene; (p)



68th Legislature 2023 SB 67.1

1 (q) 17-alpha-methyl-4-hydroxynandrolone, also known as 17-alpha-methyl-4-hydroxy-17-beta-2 hydroxyestr-4-en-3-one; 3 (r) 17-alpha-methyl-delta, 1-dihydrotestosterone, also known as 17-beta-hydroxy-17-alpha-methyl-4 5- alpha-androst-1-en-3-one, 17-alpha-methyl-1 testosterone; 5 (s) 19-nor-4-androstenediol, also known as 3-beta-17-beta-dihydroxyestr-4-ene; or 3-alpha-17beta- dihydroxyestr-4-ene; 6 7 19-nor-4-androstenedione, also known as estr-4-en-3,17-dione; (t) 8 (u) 19-nor-5-androstenediol, also known as 3-beta,17-beta-dihydroxyestr-5-ene; or 3-alpha,17-9 beta- dihydroxyestr-5-ene: 10 (v) 19-nor-5-androstenedione, also known as estr-5-en-3,17-dione; 11 (w) calusterone, also known as 7-beta, 17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3-one); 12 (x) 19-Nor-4,9(10)-androstadienedione, also known as estra-4,9(10)-diene-3,17-dione; 13 (y) bolasterone, also known as (7-alpha-dimethyl)-17-beta-hydroxyandrost-4-ene-3-one; 14 boldenone, also known as 17-beta-hydroxyandrost-1,4,-diene-3-one; (z) 15 (aa) boldione, also known as androsta-1,4-diene-3,17-dione; 16 (bb) chlorotestosterone, also known as 4-chlortestosterone; 17 clostebol; (cc) 18 (dd) delta-1-dihydrotestosterone, also known as (17-beta-hydroxy-5-alpha-androst-1-en-3-one), 1-19 testosterone; 20 dehydrochloromethyltestosterone, also known as 4-chloro-17-beta-hydroxy-17-alpha-(ee) 21 methylandrost- 1,4-dien-3-one; 22 (ff) desoxymethyltestosterone, also known as 17-alpha-methyl-5-alpha-androst-2-en-17-beta-ol; 23 (gg) dihydrochlormethyltestosterone; 24 dihydrotestosterone, also known as 4-dihydrotestosterone; (hh) 25 (ii) drostanolone, also known as 17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 26 (jj) ethylestrenol, also known as 17-alpha-ethyl-17-beta-hydroxyestr-4-ene; 27 (kk) fluoxymesterone, also known as 9-fluoro-17-alpha-methyl-11-beta, 17-beta-dihydroxyandrost-28 4-en-3-one;



1		(II)	formebulone, also known as 2-formyl-17-alpha-methyl-11-alpha,17-beta-dihydroxyandrost-1,4-
2	dien-3-one or formebolone;		
3		(mm)	furazabol, also known as 17-alpha-methyl-17-beta-hydroxyandrostano-[2,3-c]-furazan;
4		(nn)	mestanolone, also known as 17-alpha-methyl-17-beta-hydroxy-5-alpha-androstan-3-one;
5		(00)	mesterolone, also known as 1-alpha-methyl-17-beta-hydroxy-(5-alpha)-androstan-3-one;
6		(pp)	methandienone, also known as 17-alpha-methyl-17-beta-hydroxyandrost-1,4-diene-3-one;
7		(qq)	methandranone;
8		(rr)	methandriol, also known as 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-one;
9		(ss)	methandrostenolone, also known as (17-beta)-17-hydroxy-17-methylandrosta-1,4-dien-3-one;
10		(tt)	methasterone, also known as 2-alpha-17-alpha-dimethyl-5-alpha-androstan-17-beta-ol-3-one;
11		(uu)	methenolone, also known as 1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-one;
12		(vv)	methyldienolone, also known as 17-alpha-methyl-17-beta-hydroxyestra-4,9-(10)-dien-3-one;
13		(ww)	methyltestosterone, also known as 17-alpha-methyl-17-beta-hydroxyandrost-4-en-3-one;
14		(xx)	methyltrienolone, also known as 17-alpha-methyl-17-beta-hydroxyestra-4,9,11-trien-3-one;
15		(yy)	mibolerone, also known as 17-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3-one;
16		(zz)	nandrolone, also known as 17-beta-hydroxyestr-4-en-3-one;
17		(aaa)	norbolethone, also known as 13-beta,17-alpha-diethyl-17-beta-hydroxygon-4-en-3-one;
18		(bbb)	norclostebol, also known as 4-chloro-17-beta-hydroxyestr-4-en-3-one;
19		(ccc)	norethandrolone, also known as 17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-one;
20		(ddd)	normethandrolone, also known as 17-alpha-methyl-17-beta-hydroxyestr-4-en-3-one;
21		(eee)	oxandrolone, also known as 17-alpha-methyl-17-beta-hydroxy-2-oxa-(5-alpha)-androstan-3-
22	one;		
23		(fff)	oxymestrone, also known as 17-alpha-methyl-4,17-beta-dihydroxyandrost-4-en-3-one;
24		(ggg)	oxymetholone, also known as 17-alpha-methyl-2-hydroxymethylene-17-beta-hydroxy-(5-alpha)-
25	androst	an-3-on	e;
26		(hhh)	prostanozol, also known as 17-beta-hydroxy-5-alpha-androstano[3,2-c]pryazole;
27		(iii)	stanolone;
28		(jjj)	stanozolol, also known as 17-alpha-methyl-17-beta-hydroxy-(5-alpha)-androst-2-eno-(3,2-c)-



68th Legislature 2023 SB 67.1

1	pyrazole;		
2	(kkk)	stenbolone, also known as 17-beta-hydroxy-2-methyl-5-alpha-androst-1-en-3-one;	
3	(III)	talbutal, also known as 5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;	
4	(mmm	testolactone, also known as 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid	
5	lactone;		
6	(nnn)	testosterone, also known as 17-beta-hydroxyandrost-4-en-3-one;	
7	(000)	trenbolone, also known as 17-beta-hydroxyestr-4,9,11-trien-3-one; or	
8	(ppp)	tetrahydrogestrinone, also known as 13-beta,17-alpha-diethyl-17-beta-hydroxygon-4,9,11-trien-	
9	3-one.		
10	(6)	Hallucinogenic substances include dronabinol (synthetic) in sesame oil and encapsulated in a	
11	soft gelatin cap	sule in a United States food and drug administration-approved drug product, also known as (6-	
12	alpha-R-trans)-6-alpha,7,8,10-alpha-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol or (-)-delta-9		
13	(trans)-tetrahydrocannabinol.		
14	(7)	Anticonvulsant substances include perampanel."	
15			
16	Sectio	n 4. Section 50-32-229, MCA, is amended to read:	
17	"50-32	-229. Specific dangerous drugs included in Schedule IV. Schedule IV consists of the drugs	
18	and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this		
19	section.		
20	(1)	Narcotic drugs. Unless specifically excepted or listed in another schedule, any material,	
21	compound, mixture, or preparation containing any of the following narcotic is a drug, including its salts		
22	calculated as the free anhydrous base or alkaloid in the following limited quantities:		
23	(a)	not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per	
24	dosage unit;		
25	(b)	butorphanol;	
26	(c)	dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);	
27	(d)	difenoxin 1mg/25ug AtSO4/du;	



(e)

pentazocine; and

28

4

5

68th Legislature 2023 SB 67.1

1 (f) tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol).

2 (2) Depressants. Unless specifically excepted or listed in another schedule, any material,

3 compound, mixture, or preparation that contains any quantity of the following substances is a depressant,

including salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of

isomers is possible within the specific chemical designation:

- 6 (a) alprazolam;
- 7 (b) barbital;
- 8 (c) brexanolone;
- 9 (c)(d) bromazepam;
- 10 (d)(e) camazepam;
- 11 $\frac{(e)(f)}{(e)}$ chloral betaine;
- 12 (f)(g) chloral hydrate;
- 13 (g)(h) chlordiazepoxide;
- 14 (h)(i) clobazam;
- 15 (i)(j) clonazepam;
- 16 (j)(k) clorazepate;
- 17 (k)(l) clotiazepam;
- 18 (l)(m) cloxazolam;
- 19 (n) daridorexant;
- 20 (m)(o) delorazepam;
- 21 $\frac{(n)(p)}{(p)}$ diazepam;
- 22 (o)(q) dichloralphenazone;
- 23 $\frac{(p)(r)}{(p)}$ estazolam;
- 24 (q)(s) ethchlorvynol;
- 25 (r)(t) ethinamate;
- 26 (s)(u) ethyl loflazepate;
- 27 (t)(v) fludiazepam;
- 28 (u)(w) flunitrazepam;



```
1
              <del>(v)</del>(x)
                      flurazepam;
 2
                      fospropofol, also known as lusedra;
              <del>(w)</del>(y)
 3
              (x)(z)
                      halazepam;
              (y)(aa) haloxazolam;
 4
 5
              (z)(bb) ketazolam;
 6
                      lemborexant;
              (cc)
 7
              (aa)(dd) loprazolam;
 8
              (bb)(ee) lorazepam;
 9
              (cc)(ff) lormetazepam;
10
              (dd)(gg) mebutamate;
11
              (ee)(hh) medazepam;
12
              (ff)(ii) meprobamate;
13
              (gg)(jj) methohexital;
              (hh)(kk) methylphenobarbital, also known as mephobarbital;
14
15
              (ii)(II) midazolam;
16
              (jj)(mm) nimetazepam;
17
              (kk)(nn) nitrazepam;
18
              (II)(oo) nordiazepam;
19
              (mm)(pp) oxazepam;
20
              (nn)(qq) oxazolam;
21
              (oo)(rr) paraldehyde;
22
              (pp)(ss) petrichloral;
23
              (qq)(tt) phenobarbital;
24
              (rr)(uu) pinazepam;
25
              (ss)(vv) prazepam;
26
              (tt)(ww) quazepam;
27
                      remimazolam;
28
              (uu)(yy) temazepam;
```



68th Legislature 2023 SB 67.1

1 (vv)(zz) tetrazepam; 2 (ww)(aaa) triazolam; 3 (xx)(bbb) zaleplon; 4 (yy)(ccc) zolpidem; and 5 (zz)(ddd) zopiclone. 6 (3)Fenfluramine. Any material, compound, mixture, or preparation that contains any quantity of 7 fenfluramine, including its salts, isomers (whether optical, position, or geometric), and salts of isomers 8 whenever the existence of those salts, isomers, and salts of isomers is possible. 9 (4)Stimulants. Unless specifically excepted or listed in another schedule, any material, compound, 10 mixture, or preparation that contains any quantity of the following substances is a stimulant having a stimulant 11 effect on the central nervous system, including its salts, isomers, and salts of isomers: 12 (a) cathine, also known as (+)-norpseudoephedrine; 13 (b) diethylpropion: 14 fencamfamin; (c) 15 (d) fenproporex; 16 (e) mazindol; 17 (f) mefenorex; 18 modafinil; (g) 19 (h) pemoline, including organometallic complexes and chelates thereof; 20 (i) phentermine; 21 (j) pipradrol; 22 (k) serdexmethylphenidate; 23 (k)(l) sibutramine; and 24 solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, carbamate (m) 25 (ester)); and SPA ((-)-1-dimethylamino-1,2-diphenylethane). 26 (l)(n) 27 Ephedrine. (5)28 Except as provided in subsection (5)(b), any material, compound, mixture, or preparation that (a)



5

6

7

8

9

10

11

12

13

14

15

68th Legislature 2023 SB 67.1

contains any quantity of ephedrine having a stimulant effect on the central nervous system, including its salts,
enantiomers (optical isomers), and salts of enantiomers (optical isomers) when ephedrine is the only active
medicinal ingredient or is used in combination with therapeutically insignificant quantities of another active
medicinal ingredient.

- (b) Ephedrine does not include materials, compounds, mixtures, or preparations labeled in compliance with the Dietary Supplement Health and Education Act of 1994, 21 U.S.C. 321, et seq., that contain only natural ephedra alkaloids or extracts of natural ephedra alkaloids.
- (c) Ephedrine may be immediately accessible for use by a licensed physician in a patient care area if it is under the physician's direct supervision.
- (6) Other substances. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of carisoprodol, including its salts, isomers, and salts of isomers.
 - (7) Hypnotic substances include suvorexant.
- (8) Anorexiant substances include lorcaserin.
 - (9) Gastrointestinal substances include eluxadoline.
- 16 (10) General anesthetic substances include alfaxalone."

17

18

19

20

21

22

23

24

25

26

27

28

- **Section 5.** Section 50-32-232, MCA, is amended to read:
- "50-32-232. Specific dangerous drugs included in Schedule V. Schedule V consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this section.
- (1) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following is a narcotic drug, including its salts, calculated as the free anhydrous base or alkaloid in limited quantities as set forth in subsections (1)(a) through (1)(f), which include one or more nonnarcotic, active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
 - (a) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
- (b) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;



68th Legislature 2023 SB 67.1

1 (c) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams; 2 (d) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine 3 sulfate per dosage unit; not more than 100 milligrams of opium per 100 milliliters or per 100 grams; and 4 (e) (f) 5 not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate 6 per dosage unit. 7 (2) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any 8 material, compound, mixture, or preparation that contains any quantity of pyrovalerone is a stimulant having a 9 stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers. 10 (3)Depressants. Unless specifically exempted or excluded or unless listed in another schedule, 11 any material, compound, mixture, or preparation that contains any quantity of the following substances is a 12 depressant having a depressant effect on the central nervous system, including its salts, isomers, and salts of 13 isomers: 14 lacosamide, also known as (R)-2-acetoamido-N-benzyl-3-methoxy-propionamide or vimpat; (a) 15 and 16 (b) pregabalin, also known as (S)-3-(aminomethyl)-5-methylhexanoic acid or lyrica. 17 (4) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol, also known as (2-[1R-3-18 19 methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yll-5-pentyl-1,3-benzenediol), derived from cannabis and no more 20 than 0.1% (w/w) residual tetrahydrocannabinols. 21 Anticonvulsant substances include the following: (5)(4) 22 (a) ezogabine; and 23 (b) brivaracetam; 24 (c) cenobamate; and 25 (d) ganaxalone. 26 (5)Antimigraine substances including lasmiditan." 27 - END -

